diagnost tool
quest deliv beat winner tax reform
guid solid buy rais pt
deliv good highlight top bottom line beat introduc
guidanc our/street prior estim disagre stock movement
post-earn come away call feel better setup
pois benefit close deal expect
acceler pace accret acquisit profession lab servic agreement
hospit reiter buy rais pt
tax reform pama materi drawback compani tax reform
offset pama cut least view like provid path
acceler opinion arguabl attract pama
tax reform year ago quest expect tax rate drop
major reduct
tax reinvest quest indic us expect invest save
tax back busi technolog improv
enhanc user experi consum initi etc tax save drop
bottom line plan reinvest organ growth busi
expect invest inorgan acquir hospit outreach lab
beat adj ep beat rev
beat street revenue /req increas
match us beat street
volum volum grew slightli street
organ volum grew line indic alreadi
experienc nearli much weather impact due snow/ic
larg occur southern part coast
acquisit complet acquisit ad point revenu
growth manag guid assum point growth acquisit
contract understand contract aet contract
multipl year indic hope gain access
larg book busi seem approach negoti
may choos go non-exclus includ lh next year would
posit happen plan anoth analyst day fall
adj ep reclass prior restat chang present adj dilut
ep exclud excess tax benefit etb associ stock-bas comp restat
estim show number would new
account chang provid meaning comparison
guid model initi revenue guid y/i well
prior guid adj ep updat revenue
estim restat base model rev
model adj ep
estim exclud acquisit announc yet
price close busi februari
largest clinic laboratori us
focus routin gene-bas esoter test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
consum report myquest mobil applic use
nearli user increas user oper
safeway store state initi goal locat open six
locat store
buy unchang target price februari
diagnost tool
canaccord genuiti estim compani report
buy unchang target price februari
diagnost tool
canaccord genuiti estim compani report
buy unchang target price februari
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti inc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin februari et
date time product februari et
price target use multipl adj ep estim
laboratori corpor america hold lh
pt use multipl adj ep estim
risk achiev target price valuat
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
buy unchang target price februari
diagnost tool
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
